Latest news with #HOLX
Yahoo
3 days ago
- Business
- Yahoo
What Are Wall Street Analysts' Target Price for Hologic Stock?
Marlborough, Massachusetts-based Hologic, Inc. (HOLX) develops, manufactures, and supplies diagnostic products, imaging systems, and surgical products for women's health, helping in the early detection and treatment of diseases worldwide. With a market cap of $15.1 billion, Hologic operates through Diagnostics, Breast Health, GYN Surgical, and Skeletal Health segments. The company has significantly underperformed the broader market over the past year. HOLX stock has declined 15.4% over the past 52 weeks and 4.3% on a YTD basis, lagging behind the S&P 500 Index's ($SPX) 19% surge over the past year and 10% returns in 2025. More News from Barchart Why This Cannabis Penny Stock Could Be Wall Street's Next Meme Trade Breakout Peter Thiel-Backed Bullish Is About to IPO. Should You Buy BLSH Stock? Apple Stock Is Gaining Momentum, Is AAPL Stock a Buy? Stop Missing Market Moves: Get the FREE Barchart Brief – your midday dose of stock movers, trending sectors, and actionable trade ideas, delivered right to your inbox. Sign Up Now! Narrowing the focus, Hologic has also underperformed the industry-focused iShares U.S. Medical Devices ETF's (IHI) 10.3% gains over the past 52 weeks and 5.9% returns in 2025. While Hologic has underperformed the broader market over the past year, it has observed significant gains in recent months. Its stock prices have shot up more than 20% in the past three months alone. Further, HOLX stock gained 2.8% in the trading session following the release of its better-than-expected Q3 results on Jul. 30. The company's topline for the quarter inch up 1.2% year-over-year to $1.02 billion, surpassing the consensus estimates by 1.7%. Moreover, its adjusted EPS grew by 1.9% to $1.08, coming ahead of the management's guidance range and beating the Street's expectations by 2.9%. For the full fiscal 2025, ending in September, analysts expect Hologic to deliver an adjusted EPS of $4.24, up 3.9% year-over-year. The company has a mixed earnings surprise history. While it missed the Street's bottom-line estimates once over the past four quarters, it surpassed the projections on three other occasions. The stock has a consensus 'Moderate Buy' rating overall. Of the 19 analysts covering the stock, opinions include six 'Strong Buys,' two 'Moderate Buys,' and 11 'Holds.' This configuration is slightly more optimistic than two months ago, when five analysts gave 'Strong Buy' recommendations and only one analyst suggested a 'Moderate Buy' rating. On Aug. 6, RBC Capital analyst Conor McNamara upgraded HOLX from 'Sector Perform' to 'Outperform' and raised the price target from $72 to $87. As of writing, Hologic's mean price target of $73 suggests a modest 5.8% upside potential from current price levels. On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
10-08-2025
- Business
- Yahoo
Hologic Focuses on Breast Health Turnaround This Year: Can It Deliver?
Hologic HOLX has built a resilient Breast Health business, with its mammography products holding a leading market share. The division struggled this year, with revenues decreasing 2.1% and 6.9% in the first and second quarters of fiscal 2025, respectively, due to an anticipated slowdown in soft capital equipment sales and budget constraints among private and government hospital customers abroad. Nonetheless, Hologic expects Breast Health to return to healthy growth in the fourth quarter. A new leadership team is now in place and has already made progress in three key areas, setting the stage for better future growth. One of these was to create a clear separation between the capital and disposable product sales representatives, aligning the different skill sets required for these sales processes. Hologic believes that this reorganization, along with a more defined selling strategy, will lead to a clearer focus and improved performance within its commercial channels. In addition, the sales team has refined its end-of-life strategy for aging gantries that remain in the field. With clear visibility into the locations of these older units, Hologic is launching a new offensive strategy that actively encourages customers and its sales reps to pursue upgrading them. The Endomagnetics acquisition in 2024 expanded Hologic's presence in the interventional breast health market, adding wireless breast surgery localization and lymphatic tracing solutions to its portfolio. The business presumably entered the second half of fiscal 2025 with strong momentum. Hologic has implemented a direct sales approach for Endomagnetics products in North America, replacing the previously used distributor. Service revenues tend to provide greater stability, rising 12% year over year in the second quarter and accounting for 21% of Hologic's total revenues. With Endomagnetics now a part, Hologic has enough scale to emphasize more on recurring revenues, alongside a capital sales focus. This is expected to support the upcoming Envision platform launch and also maximize the reach of Endomag products and services. Updates From Hologic's Breast Health Peers GE Healthcare GEHC and RadNet RDNT are two prominent players competing with Hologic in the breast health space. GEHC recently announced the commercial availability of an advanced floor-mounted digital X-ray system, Definium Pace Select ET, to deliver high-image quality and optimize efficiency in highly demanding environments while enhancing access and affordability. GE Healthcare's Women's Health products use X-ray technology to help clinicians screen for and diagnose breast cancer, as well as bone and metabolic diseases in women. RadNet's subsidiary, DeepHealth, recently completed the acquisition of iCAD, Inc. — a global leader in AI-powered breast health solutions. The addition of iCAD's extensive AI portfolio, including breast cancer detection, risk evaluation, breast density and breast arterial calcification assessment, significantly boosts RadNet's Digital Health segment. HOLX Stock Performance, Valuation and Estimates Over the past year, Hologic shares have declined 20.4% compared with the industry's 10.5% fall. Image Source: Zacks Investment Research Hologic is trading at a forward 12-month price-to-earnings of 3.45X, lower than the industry average of 4.17X. The stock carries a Value Score of B at present. Image Source: Zacks Investment Research Hologic's fiscal 2025 and 2026 EPS estimates have shown a bearish trend over the past 90 days. Image Source: Zacks Investment Research HOLX stock currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report RadNet, Inc. (RDNT) : Free Stock Analysis Report GE HealthCare Technologies Inc. (GEHC) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
CNBC
06-08-2025
- Business
- CNBC
RBC sees nearly 30% upside for this medical tech stock as headwinds abate
There's a rosy outlook ahead for Hologic , according to RBC Capital Markets. The bank upgraded shares of the medical technology provider to outperform from sector perform. Analyst Conor McNamara accompanied the move by raising his price target to $87 per share from $72. Shares of Hologic have slipped 6% this year, but McNamara's revised price forecast implies an upside ahead of 28%. HOLX YTD mountain HOLX YTD chart "Our new price target assumes HOLX returns to historic multiples seen when the company was growing revenue MSD [mid-single digit] and beating / raising," the analyst wrote. McNamara said he believes that Hologic's organic revenue growth guidance for fiscal year 2026 will exceed current street estimates. This could in turn boost investor confidence, "leading to a period of multiple expansion." Two recent M & A deals could also help increase the company's overall organic growth in fiscal year 2026. "We believe the buyside is discounting HOLX's recent M & A success and over-penalizing the company for recent 1x headwinds; however, we expect upside surprises in coming quarters will convince investors +MSD growth is sustainable," the analyst added. "With a clean balance sheet and multiple end-markets, we think there is ample opportunity for HOLX to continue to exploit this M & A strategy in the medium and long term." McNamara said that two of Hologic's product platforms could begin adding "meaningful growth" beginning late next year — Panther Fusion and the Genius Digital Diagnostics System. Meantime, various headwinds that plagued Hologic in fiscal year 2025 are also set to abate. For instance, China sales declined significantly in fiscal year 2025, but the company believes that these sales have bottomed out. Hologic also faced a year-over-year decline of around $100 million in breast health equipment sales, but RBC does not anticipate this to reoccur. "We think HOLX has enough wiggle room to offset any other headwinds (i.e. - continued declines in HIV testing in Africa via US policy changes)," McNamara added.
Yahoo
31-07-2025
- Business
- Yahoo
Hologic Inc (HOLX) Q3 2025 Earnings Call Highlights: Surpassing Expectations Amidst Challenges
Total Revenue: $1.024 billion, a slight growth of 0.4%, exceeding guidance by $14 million. Non-GAAP Earnings Per Share (EPS): $1.08, a 1.9% increase year-over-year, exceeding guidance by a penny. Non-GAAP Operating Margin: Just above 30%. Diagnostics Revenue: $448.9 million, 0.9% growth, 2.9% organically excluding COVID-related sales. Breast Health Revenue: $365.2 million, declined 5.8%, 10.8% organically excluding Endomagnetics and SSI. Surgical Revenue: $178.4 million, increased 6.3%, 1.2% organically excluding Gynesonics. Skeletal Revenue: $31.3 million, grew 62.1%. Non-GAAP Gross Margin: 60.3%, an 80 basis points decline year-over-year. Operating Expenses: $309.6 million, increased 2.2%. Net Margin: 23.8%, decreased 100 basis points year-over-year, increased 60 basis points sequentially. Operating Cash Flow: $343 million. Cash and Short-term Investments: $1.88 billion. Net Leverage Ratio: 0.6 times. Fourth Quarter Revenue Guidance: $1.03 billion to $1.04 billion. Fourth Quarter Non-GAAP EPS Guidance: $1.09 to $1.12. Full Year Revenue Guidance: $4.081 billion to $4.091 billion. Full Year Non-GAAP EPS Guidance: $4.23 to $4.26. Warning! GuruFocus has detected 2 Warning Sign with HOLX. Release Date: July 30, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Hologic Inc (NASDAQ:HOLX) exceeded its revenue and non-GAAP earnings per share guidance for the third quarter of fiscal 2025. The diagnostics business showed growth, with molecular diagnostics leading the way, particularly in the United States. The breast health business showed sequential improvement, with positive contributions from the skeletal franchise as supply constraints lifted. Endomagnetics, acquired last summer, contributed nearly $20 million in revenue with a healthy gross margin, exceeding deal expectations. The company has made significant progress in mitigating tariff impacts, reducing expected quarterly tariff expenses by half. Negative Points Breast health revenues declined by 5.8% compared to the prior year, although this was expected. The operating environment in China and reduced funding for HIV tests in Africa negatively impacted the diagnostics business. Non-GAAP gross margin decreased by 80 basis points due to product mix and a reserve recorded in the skeletal health division. Operating expenses increased by 2.2%, driven by acquisitions and increased expenses related to the deferred compensation plan. The company faces ongoing challenges with tariffs, expecting $10 million to $12 million in tariff expenses per quarter in fiscal 2026. Q & A Highlights Q: Are there any dynamics we should consider in our models for fiscal 2026, either tailwinds or headwinds, that could affect the continuation of trends? Also, was there any impact from China DRG in the quarter? A: For fiscal 2026, we expect mid-single-digit growth. Factors to consider include the discontinuation of the flu scan and ongoing headwinds related to China and HIV, which will impact the first half of fiscal 2026. Regarding China DRG, while it hasn't been a significant factor for us, the challenging environment in China has affected our business, with total China revenue down more than 50% compared to the prior year. Q: What are your thoughts on capital allocation, particularly regarding M&A, given the strong cash flow this quarter? A: We have spent over $750 million on buybacks year-to-date and feel good about our actions. We will continue to focus on both M&A and buybacks, but there are no plans for any large acquisitions at this time. Q: Can you discuss the progress and outlook for the breast health business, particularly regarding new product launches and replacement cycles? A: We are optimistic about the breast health business, having addressed previous challenges. We are excited about launching our new product, Vision, which will be significant in the latter half of 2026 and beyond. The interventional business is also becoming a strong driver, contributing to recurring revenue and better margins. Q: How do you view the diagnostic setup for fiscal 2026, considering the growth of molecular diagnostics and BV CV/TV? A: We expect diagnostics to be within the mid-single-digit growth range for fiscal 2026, despite first-half headwinds from China and HIV. The diagnostics business, particularly molecular diagnostics, continues to have significant growth potential, driven by the expansion of Panther systems and new menu offerings. Q: Can you provide more details on the tariff impacts and any further mitigation steps you might take? A: We have successfully mitigated about half of the initially anticipated tariff impacts through operational efficiencies within our supply chain. We continue to evaluate the situation, but for competitive reasons, we won't disclose specific strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.
Yahoo
25-07-2025
- Business
- Yahoo
Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics
In its upcoming report, Hologic (HOLX) is predicted by Wall Street analysts to post quarterly earnings of $1.05 per share, reflecting a decline of 0.9% compared to the same period last year. Revenues are forecasted to be $1.01 billion, representing a year-over-year decrease of 0.4%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. This represents how the covering analysts, as a whole, have reassessed their initial estimates during this timeframe. Prior to a company's earnings release, it is of utmost importance to factor in any revisions made to the earnings projections. These revisions serve as a critical gauge for predicting potential investor behaviors with respect to the stock. Empirical studies consistently reveal a strong link between trends in earnings estimate revisions and the short-term price performance of a stock. While investors typically use consensus earnings and revenue estimates as a yardstick to evaluate the company's quarterly performance, scrutinizing analysts' projections for some of the company's key metrics can offer a more comprehensive perspective. Given this perspective, it's time to examine the average forecasts of specific Hologic metrics that are routinely monitored and predicted by Wall Street analysts. The combined assessment of analysts suggests that 'Revenues- GYN surgical' will likely reach $179.82 million. The estimate points to a change of +7.9% from the year-ago quarter. Based on the collective assessment of analysts, 'Revenues- Diagnostics- Molecular diagnostics' should arrive at $316.12 million. The estimate points to a change of +1.8% from the year-ago quarter. It is projected by analysts that the 'Revenues- Diagnostics- Blood screening' will reach $5.65 million. The estimate indicates a year-over-year change of -28.5%. Analysts expect 'Revenues- Breast health- Breast imaging' to come in at $277.39 million. The estimate indicates a change of -10.3% from the prior-year quarter. Analysts predict that the 'Revenues- Total Diagnostics' will reach $437.46 million. The estimate suggests a change of -0.8% year over year. The consensus among analysts is that 'Revenues- Skeletal health' will reach $25.34 million. The estimate points to a change of +33.4% from the year-ago quarter. Analysts forecast 'Revenues- Diagnostics- Cytology and perinatal' to reach $117.36 million. The estimate indicates a year-over-year change of -4%. According to the collective judgment of analysts, 'Revenues- Total Breast health' should come in at $363.15 million. The estimate points to a change of -5.7% from the year-ago quarter. The consensus estimate for 'Revenues- Breast health- Interventional breast solutions' stands at $85.76 million. The estimate indicates a year-over-year change of +13.1%. The average prediction of analysts places 'Revenues- Service and other' at $202.73 million. The estimate indicates a year-over-year change of +1.3%. Analysts' assessment points toward 'Revenues- Product' reaching $801.50 million. The estimate points to a change of -1.2% from the year-ago quarter. View all Key Company Metrics for Hologic here>>> Hologic shares have witnessed a change of +1.5% in the past month, in contrast to the Zacks S&P 500 composite's +4.6% move. With a Zacks Rank #4 (Sell), HOLX is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> . Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hologic, Inc. (HOLX) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
